Status:
COMPLETED
Immune Checkpoint Receptors in AML-Leukemic Initiating Cells
Lead Sponsor:
University Hospital, Bordeaux
Conditions:
Acute Myeloid Leukemia
Eligibility:
All Genders
18+ years
Brief Summary
This project aim at deciphering immune mechanisms that allow the immunoescape of AML initiating cells.
Detailed Description
Leukemic Initiating Cells (LIC) were shown to play a key role in AML relapses, and are characterized by resistance to treatment and a high capacity to escape to immune system. Immune checkpoints (ICP)...
Eligibility Criteria
Inclusion
- ≥ 18 years of age
- newly diagnosed AML
Exclusion
- isolated extramedullary AML
- mixed phenotype acute leukemia
Key Trial Info
Start Date :
May 29 2018
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
June 9 2021
Estimated Enrollment :
199 Patients enrolled
Trial Details
Trial ID
NCT03449745
Start Date
May 29 2018
End Date
June 9 2021
Last Update
April 20 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
CHU de Bordeaux
Bordeaux, France